It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs

As AAV manufacturing enters its third generation, cell line engineering can enable enhanced productivity, scalability, and quality of viral vectors. A range of cell line options can allow therapy developers to tailor the choice for each therapeutic program and seamlessly transition from R&D through manufacturing as needs evolve. Furthermore, cell line engineering can tackle some of the inherent quality issues like host cell DNA (hcDNA) inside capsids, an impurity that cannot be removed in current downstream processing. This article will address how advanced engineered cell lines can empower researchers and developers to realize the full potential of gene therapy. New methods to harness cell line engineering to improve AAV through quality by design will be explored, alongside new performance data acquired with ELEVECTA™ cell lines.

Please enter your email to access content Read now